NASDAQ:ADAP
Delisted

Adaptimmune Therapeutics Stock Signals

etoro logo Buy ADAP
*Your capital is at risk
$0.0549
+0 (+0%)
At Close: Feb 20, 2026

Latest Data & Signals Issued

Below are some of the latest signals issued for Adaptimmune Therapeutics plc

General

Signal Type Signal Value Data
Score 0.000 78 days ( 0 %
Last Price $0.0549 0 %
Performance History
7 Days
$0.0549 $0.0549
0%
30 Days
$0.0549 $0.0549
0%
12 Mos
$0.580 $0.0549
-90.53%

3/18

Active Buy Signals

Specific Signals

Short Term
Net score: 50
Signal Type Signal Value Importance Data
High / Low N/A Very Low $0.0549 - $0.0549
Trend - 3 mos 1.11 % High Width: 12.58 %
Pred. range - 3 mos $0.0497 - $0.0559 Low -9.55 % - 1.83 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Sell Very Low Feb 19, 2026 - 2 days
RSI Short Pivot Signal Sell Very Low Nov 30, -0001 - N/A days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Buy Medium Dec 12, 2025 - 47 days
Short/Long MA 3 mos Buy Medium Dec 12, 2025 - 47 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 5.91
Signal Type Signal Value Importance Data
Trend - 12 mos -76.27 % Very High Width: 179.32 %
Pred. range - 12 mos N/A - $0.0289 High -100.00 % - -47.42 %
Short MA 12 mos Sell Very High Oct 17, 2025 - 86 days
Long MA 12 mos Sell Very High Oct 17, 2025 - 86 days
Short/Long MA 12 mos Sell Very High Nov 30, -0001 - N/A days
Pivot Long Sell Low Feb 19, 2026 - 2 days
RSI Long Pivot Signal Sell Low Nov 19, 2025 - 63 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT ADAPTIMMUNE THERAPEUTICS PLC
Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.84
4.82% Jun 11
EAT
$140.46
11.23% Jun 05
TPR
$140.47
7.49% Jun 04
LITE
$905.00
5.77% Jun 01
W
WCLD
$27.34
12.84% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE